PAI-1 is involved in delayed bone repair induced by glucocorticoids in mice

Bone. 2020 May:134:115310. doi: 10.1016/j.bone.2020.115310. Epub 2020 Mar 3.

Abstract

Glucocorticoid (GC) treatments induce osteoporosis and chronic GC treatments have been suggested to induce delayed bone repair; however, the mechanisms by which GC induces delayed bone repair remain unclear. We herein investigated the roles of plasminogen activator inhibitor-1 (PAI-1) in GC-induced effects on bone repair after femoral bone injury using female mice with a PAI-1 deficiency and their wild-type counterparts. Dexamethasone (Dex) increased plasma PAI-1 levels as well as PAI-1 mRNA levels in the adipose tissues and muscles of wild-type mice. PAI-1 deficiency significantly blunted Dex-induced delayed bone repair in mice. Moreover, PAI-1 deficiency significantly blunted Runx2 mRNA levels suppressed by Dex as well as Dex-induced osteoblast apoptosis at the damaged site 7 days after bone injury in mice. On the other hand, PAI-1 deficiency did not affect adipogenic gene expression enhanced by Dex at the damaged site 7 days after bone injury in mice. In conclusion, we herein showed for the first time that PAI-1 is involved in delayed bone repair after bone injury induced by GC in mice. PAI-1 may influence early stage osteoblast differentiation and apoptosis during the osteoblastic restoration phase of the bone repair process.

Keywords: Bone repair; Glucocorticoids; Osteoblast; Plasminogen activator inhibitor-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Differentiation
  • Dexamethasone / pharmacology
  • Female
  • Glucocorticoids*
  • Hemorrhagic Disorders*
  • Mice
  • Mice, Knockout
  • Osteoblasts*
  • Plasminogen Activator Inhibitor 1* / genetics

Substances

  • Glucocorticoids
  • Plasminogen Activator Inhibitor 1
  • Dexamethasone